结合三个器官等价物和转录组的微生理系统来评估化品成分的毒理终点
Nathalia de Carvalho Indolfo1,2, Melissa Dibbernn Ganzerla3,4, Tábata Renée Doratioto1
1Natura Cosméticos S.A., Cajamar, São Paulo, Brazil.
Lab on a chip
|November 3, 2023
概括
一个新的三器官微生理系统 (MPS) 为化品安全提供了对动物试验的可靠,道德的替代方案. 这种先进的模型准确评估化学毒性,支持消费者安全和远离动物试验.
科学领域:
- 毒理学 毒理学 毒理学
- 生物技术是生物技术.
- 在体外建模模型.
背景情况:
- 在全球范围内,越来越多地禁止对化品的动物试验,从而产生了对替代安全评估方法的需求.
- 现有的体外试验方法往往缺乏足够的复杂性,无法完全预测体内毒理学结果.
- 微生理系统 (MPS) 为传统测试提供了更具预测性和生理相关性的替代方案.
研究的目的:
- 提出一种新的三器官微流体微生理系统 (MPS),集成皮肤,肝脏和肠道等价物.
- 评估这个MPS在评估化学品毒理终点方面的潜力.
- 为了证明MPS在化品成分安全性评估的综合方法中的实用性.
主要方法:
- 开发一个模仿人类器官相互作用的三器官微流体系统.
- 应用MPS对化学物质的毒理学评估.
- 将基因表达分析与MPS集成在一起,以进行全面的终点评估.
主要成果:
- 三个器官的MPS成功地模仿了与化学物质暴露相关的器官间动态.
- 使用MPS有效评估了测试化学品的毒理终点.
- 该系统在安全评估方面表现出高的预测能力,与传统方法相比或超过.
结论:
- 开发的微生理系统为化品成分安全性评估提供了一个可靠和道德的平台.
- 这种MPS技术支持全球化品行业的动物试验转变.
- 该系统显示了评估各种化学品和确保消费者安全的巨大潜力.
相关概念视频
Toxic Reactions: Overview
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...


